Evaluation of the combined effects of doxorubicin and bortezomib on the human acute lymphoblastic leukemia cell line

1. Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcade™) in the treatment of multiple myeloma, Ther and Clin Risk Manag. 2006; 2:271-9.Search in Google Scholar

2. Romaniuk W, Ołdziej AE, Zińczuk J, Kłoczko J. Proteasome inhibitors in cancer therapy. Postepy Hig Med Dosw. 2015;69: 1443-50.Search in Google Scholar

3. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16:3267-85.10.2174/09298670978880331219548866Search in Google Scholar

4. Lipchick BC, Fink EE, Nikiforov MA. Oxidative stress and proteasome inhibitors in multiple myeloma. Pharmacol Res. 2016; 105:210-5.10.1016/j.phrs.2016.01.029504486626827824Search in Google Scholar

5. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257-64.10.1182/blood-2005-05-209116166592Search in Google Scholar

6. Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells. J Biol Chem. 2003;278: 33714-23.10.1074/jbc.M30255920012821677Search in Google Scholar

7. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol. 2004;24:9695-704.10.1128/MCB.24.22.9695-9704.200452547415509775Search in Google Scholar

8. Ning YM, He K, Dagher R, Sridhara R, Farrell AT, Justice R et al. Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma. Oncology. 2007;21:1503-8.Search in Google Scholar

9. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC et al. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15:230-69.10.6004/jnccn.2017.002328188192Search in Google Scholar

10. https://clinicaltrials.gov/ct2/results?cond=&term=bortezomib%2C+doxorubicin&cntry=&state=&city=&dist= open access: 01.09.2018Search in Google Scholar

11. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal. 2017;7:e577.10.1038/bcj.2017.53552040028665419Search in Google Scholar

12. ClinicalTrials.gov Identifier: NCT00440726Search in Google Scholar

13. https://clinicaltrials.gov/ct2/show/NCT00440726?term=bortezomib%2C+doxorubicin&cond=ALL%2C+Childhood&rank=1 open access: 01.09.2018Search in Google Scholar

14. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther and Clin Risk Manag. 2009;5:151-9.Search in Google Scholar

15. Horton TM, Gannavarapu A, Blaney SM, D’Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58:13-23.10.1007/s00280-005-0135-z16292537Search in Google Scholar

16. Irimia R, Tofolean IT, Sandu RG, Băran OE, Ceauşescu MC, Coşoreanu V et al. Quercetin, Menadione, Doxorubicin combination as a potential alternative to Doxorubicin monotherapy of acute lymphoblastic leukemia. Documenta Haematologica. 2015;24.10.1515/dch-2015-0005Search in Google Scholar